Molnupiravir can reduce the risk of hospitalization or death by around 30% when taken shortly after testing positive for COVID-19, and is a somewhat effective treatment option when superior alternatives such as Paxlovid  (nirmatrelvir/ritonavir) are unavailable or unsuitable.

This factsheet developed by IMPAACT4C19 and Treatment Action Group lays out all that you need to know about molnupiravir: what it is, how to take it, who should use it (and who should not,) and how it interacts with other drugs. This guide can help inform treatment decisions during the ongoing COVID-19 pandemic, particularly for people living with HIV, TB and HCV, and is the second publication in a three-part series on Test-and-Treat interventions for COVID-19. This publication follows a factsheet on Paxlovid, and will be proceeded by one on rapid testing and self-testing.